Pharmaids Pharmaceuticals has provided a corporate guarantee of ₹0.55 crore to its subsidiary, Adita Bio Sys Private Limited, for a loan under the ECLGS 5.0 scheme. The board had approved a limit of ₹0.75 crore. This creates a contingent liability but has no immediate financial impact on Pharmaids.

Pharmaids Pharmaceuticals Ltd. Board Approves Corporate Guarantee

₹0.75 crore

₹0.55 crore

What just happened

Pharmaids Pharmaceuticals Limited announced that it has executed a corporate guarantee of ₹0.55 crore with the State Bank of India for a loan facility to its material subsidiary, Adita Bio Sys Private Limited. This guarantee is part of the Emergency Credit Line Guarantee Scheme (ECLGS) 5.0.

Why this matters

The guarantee provides financial support to the subsidiary, enabling it to secure necessary funding. While it creates a contingent liability for Pharmaids Pharmaceuticals, the company has stated it has no immediate financial impact on the listed entity. The board had previously approved a limit of up to ₹0.75 crore for such guarantees.

The backstory

Pharmaids Pharmaceuticals is the parent company, and Adita Bio Sys Private Limited is its material subsidiary. Providing corporate guarantees for subsidiaries is a common practice to facilitate their financing needs, especially for government-backed schemes aimed at supporting businesses.

What changes now

Pharmaids Pharmaceuticals now has an executed corporate guarantee of ₹0.55 crore outstanding. The board-approved limit for such guarantees remains at ₹0.75 crore. The company will be monitoring the subsidiary's performance related to this loan.

Risks to watch

The primary risk is that if the subsidiary defaults on its loan, Pharmaids Pharmaceuticals will be liable to pay the guaranteed amount. Currently, the company states no immediate financial impact, but this contingent liability needs to be watched.

Peer comparison

Providing financial guarantees for subsidiaries is a standard corporate finance activity. Many listed companies extend such support to their key subsidiaries to aid growth and operational needs, especially under specialized credit schemes.

Context metrics (time-bound)

The Board of Directors approved the guarantee limit on May 29, 2026. The executed guarantee amount is ₹0.55 crore (₹55 lakh).

What to track next

Investors should monitor the subsidiary's financial performance and its ability to service the loan. Any future utilization of the remaining guarantee limit or changes in the contingent liability status should also be tracked.